

In re Patent Application of

MAERTENS et al.

Atty. Ref.:

TECHCHIER BOOM 2551-108

Serial No.

09/973,025

Group:

1648

Filed:

October 10, 2001

Examiner:

Li

For:

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS

FOR DIAGNOSTIC AND THERAPEUTIC USE

Assistant Commissioner for Patents Washington, DC 20231

September 9, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

<u> </u>	PTO-1449 Pursuant to 37 CFR 1.97(b)
	[within 3 months of filing or prior to 1st Office Action on the merits]
	N/C

- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)** [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C
- M 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) \$180.00 Statement or Rule 17(p) fee)]
- 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00


The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

 \bowtie A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is

09/10/2003 SDENBOB1 00000104 09973025

03 FC:1806

180.00 OP




enclosed herewith.

Also attached is a copy of the pending claims in related copending application Serial No. 08/928,757 and copending application Serial No. 09/899,303. Consideration of the attached claims is requested.

This paper is submitted in accordance with: 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] \boxtimes 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and a) The required Statement made in item 8 below; or X b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) 7. Statement and Rule 17(p) fee), but before final fee payment]; and a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and b) The required Statement is stated in item 8 below. 8. Statement under 37 CFR 1.97(e) a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or No item of information contained in this Information Disclosure Statement b) was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. X 9. Please charge all deficiency fees associated with the submission of this

Information Disclosure Statement and any other fees applicable to this

application to Deposit Account No. 14-1140. An original and one (1) copy of



this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100